<code id='C991D26098'></code><style id='C991D26098'></style>
    • <acronym id='C991D26098'></acronym>
      <center id='C991D26098'><center id='C991D26098'><tfoot id='C991D26098'></tfoot></center><abbr id='C991D26098'><dir id='C991D26098'><tfoot id='C991D26098'></tfoot><noframes id='C991D26098'>

    • <optgroup id='C991D26098'><strike id='C991D26098'><sup id='C991D26098'></sup></strike><code id='C991D26098'></code></optgroup>
        1. <b id='C991D26098'><label id='C991D26098'><select id='C991D26098'><dt id='C991D26098'><span id='C991D26098'></span></dt></select></label></b><u id='C991D26098'></u>
          <i id='C991D26098'><strike id='C991D26098'><tt id='C991D26098'><pre id='C991D26098'></pre></tt></strike></i>

          Home / fashion / explore

          explore


          explore

          author:hotspot    Page View:76674
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In